Polatuzumab

Leading oncology CMOs express concern over the overwhelming volume of practice-changing data emerging from major conferences, making it increasingly difficult for physicians to stay current with optimal treatment approaches.

Polatuzumab, a first-in-class anti-CD79b antibody-drug conjugate, has been approved in India for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL).

Leading oncology CMOs express concern over the overwhelming volume of practice-changing data emerging from major conferences, making it increasingly difficult for physicians to stay current with optimal treatment approaches.